Influence of C Upsilon P2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis
- 주제(키워드) losartan , E-3174 , C Upsilon P2C9 , polymorphism , pharmacokinetics
- 주제(기타) Health Care Sciences & Services
- 주제(기타) Medicine, General & Internal
- 설명문(일반) [Gwak, Hye-Sun] Ewha Womans Univ, Coll Pharm, Seoul 03760, South Korea; Ewha Womans Univ, Grad Sch Pharmaceut Sci, Seoul 03760, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 MDPI
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000182338
- 본문언어 영어
- Published As http://dx.doi.org/10.3390/jpm11070617
초록/요약
This study aimed to investigate the influence of C Upsilon P2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used PubMed, the Cochrane Library, EMBASE, and Web of Science, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The data analysis was conducted through Review Manager (RevMan), version 5.3, and R software. We found that healthy volunteers with C Upsilon P2C9*2 or *3 carriers had higher area under the curve (AUC(0-infinity)) of losartan (mean difference (MD) 0.17 mu g.h/mL; 95% confidence intervals (CI): 0.04, 0.29) and lower AUC(0-infinity) of E-3174 (MD -0.35 mu g.h/mL; 95% CI: -0.62, -0.08) than those with C Upsilon P2C9*1/*1. Subjects with C Upsilon P2C9*2 or *3 carriers showed lower maximum concentration (C-max) of E-3174 than those with C Upsilon P2C9*1/*1 (MD -0.13 mu g/mL; 95% CI: -0.17, -0.09). For half-life, subjects with C Upsilon P2C9*2 or *3 carriers had longer half-lives of losartan and E-3174 than those with C Upsilon P2C9*1/*1 (MD 0.47 h; 95% CI: 0.32, 0.61 and MD 0.68 h; 95% CI: 0.44, 0.92, respectively). This meta-analysis suggests that the pharmacokinetics of losartan and E-3174 are associated with the C Upsilon P2C9 polymorphisms
more